Chronic treatment with Vemurafenib (Zelboraf®), a selective inhibitor of BRAF frequently used to treat melanoma bearing the BRAF-V600E mutation, affected tumor cell proliferation and apoptosis, thereby recapitulating changes in tumor morphology, without leading to any toxicity in the surrounding tissue. Here, BRAF is linked to neoplasm.